Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant inavolisib combinations in early-stage PIK3CA‑mutated breast cancer
2024-518811-20-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of inavolisib in breast cancer, sponsored by Roche. Primary endpoints: Incidence and severity of adverse events, Change from baseline in selected clinical laboratory test results and 1 more. Planned start Jul 2025; status: authorised.
02
Drugs
inavolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-518811-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518811-20-00.